Brasil, Ministério da Saúde.Secretaria de Vigilância em Saúde, 2010. Situação epidemiológica de Esquistossomose no Brasil. Grupo Técnico das Parasitárias, Sub HA/CGDT/DEVEP/SVS/MS Brasília. Available at: http://portal.saude.gov.br/portal/arquivos/pdf/situacao_esquistossomose_brasil_abril2011.pdf. Acessado em junho de 2013.
Hoffman DB, Lehman JS, Scott VC, Warren KS, Webbe G, 1979.Control of schistosomiasis: report of a workshop. Am J Trop Med Hyg 28: 249–259.
Lambertucci JR, 1993. Schistosoma mansoni: pathological and clinical aspects. Jordan P, Webbe G, Sturrock RF, eds. Human Schistosomiasis. Wallingford: Cab International, 195–225.
Lambertucci JR, dos Santos Silva LC, Andrade LM, de Queiroz LC, Carvalho VT, Voieta I, Antunes CM, 2008. Imaging techniques in the evaluation of morbidity in schistosomiasis mansoni. Acta Trop 108: 209–217.
Rodrigues VL, Otoni A, Voieta I, Antunes CM, Lambertucci JR, 2010. Glomerulonephritis in schistosomiasis mansoni: a time to reappraise. Rev Soc Bras Med Trop Nov-Dec 43: 638–642.
Lambertucci JR, Otoni A, dos Reis MA, 2007. Nephrotic syndrome in hepatosplenic schistosomiasis mansoni. Rev Soc Bras Med Trop 40: 492–493.
Lambertucci JR, Serufo JC, Gerspacher-Lara R, Rayes AA, Teixeira R, Nobre V, Antunes CM, 2000. Schistosoma mansoni: assessment of morbidity before and after control. Acta Trop 77: 101–109.
Hawkins R, 2011. New biomarkers of acute kidney injury and the cardio-renal syndrome. Korean J Lab Med 31: 72–80.
Araya CE, Wasserfall CH, Brusko TM, Mu W, Segal MS, Johnson RJ, Garin EH, 2006. A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol 21: 603–610.
Garin EH, 2000. Circulating mediators of proteinuria in idiopathic minimal lesion nephrotic syndrome. Pediatric Nephrol 14: 872–878.
Souto MF, Teixeira AL, Russo RC, Penido MG, Silveira KD, Teixeira MM, Simões E, Silva AC, 2008. Immune mediators in idiopathic nephrotic syndrome: evidence for a relation between interleukin 8 and proteinuria. Pediatr Res 64: 637–642.
Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, Warram JH, Krolewski AS, Bonventre JV, 2011. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-D-glucosaminidase. Kidney Inter 79: 464–470.
Ibrahim S, Rashed L, 2008. Correlation of urinary monocyte chemo-attractant protein-1 with other parameters of renal injury in type-II diabetes mellitus. Saudi J Kidney Dis Transpl 19: 911–917.
Mukaida N, Harada A, Matsushima K, 1998. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor. Rev Mar 9: 9–23.
Segerer S, 2003. The role of chemokines and chemokine receptors in progressive renal diseases. American J Kidney Dis 41 (Suppl 1): S15–S18.
Sun Y, Yuan S, Xu X, 2009. Expression of MCP-1 in renal tissues of patients with IgA nephropathy. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34: 1023–1028.
Silva LC, Andrade LM, de Paula IB, de Queiroz LC, Antunes CM, Lambertucci JR, 2012. Ultrasound and magnetic resonance imaging findings in Schistosomiasis mansoni: expanded gallbladder fossa and fatty hilum signs. Rev Soc Bras Med Trop Jul-Aug 45: 500–504.
Lambertucci JR, Godoy P, Neves J, Bambirra EA, Ferreira MD, 1988. Glomerulonephritis in Salmonella-Schistosoma-mansoni association. Am J Trop Med Hyg 38: 97–102.
Katz N, Chaves A, Pellegrino J, 1972. A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop São Paulo 14: 397–400.
Nyman HA, Dowling TC, Hudson JQ, Peter WL, Joy MS, Nolin TD, 2011. Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 31: 1130–1144.
Grupo de Trabalho MA, 2011. Brazilian guidelines for ambulatory monitoring of arterial pressure and III Brazilian guidelines for home monitoring of blood pressure. J Bras Nefrol Jul-Sep 33: 365–388.
Bewick V, Cheek L, Ball J, 2005. Statistics review 14: logistic regression. Crit Care 9: 112–118.
Stiglic G, Kocbek S, Pernek I, Kokol P, 2012. Comprehensive decision tree models in bioinformatics. PLoS ONE 7: e33812.
Biau G, 2012. Analysis of a random forests model. J Mach Learn Res 13: 1063–1095.
Loh WY, Shih YS, 1997. Split selection methods for classification trees. Statist Sinica 7: 815–840.
Daniel C, Schaub K, Amann K, Lawler J, Hugo C, 2007. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes 56: 2982–2989.
Sanchez-Niño MD, Sanz AB, Ihalmo P, Lassila M, Holthofer H, Mezzano S, Aros C, Groop PH, Saleem MA, Mathieson PW, Langham R, Kretzler M, Nair V, Lemley KV, Nelson RG, Mervaala E, Mattinzoli D, Rastaldi MP, Ruiz-Ortega M, Martin-Ventura JL, Egido J, Ortiz A, 2009. The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol 20: 353–362.
Hsing CH, Hsu CC, Chen WY, Chang LY, Hwang JC, Chang MS, 2007. Expression of IL-19 correlates with Th2 cytokines in uraemic patients. Nephrol Dial Transplant 22: 2230–2238.
Tesch GH, 2008. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J of Physiol Renal Physiol 294: F697–F701.
Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH, 2006. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69: 73–80.
Wu H, Wang Y, Tay YC, Zheng G, Zhang C, Alexander SI, Harris DC, 2005. DNA vaccination with naked DNA encoding MCP-1 and RANTES protects against renal injury in adriamycin nephropathy. Kidney Int 67: 2178–2186.
Vielhauer V, Berning E, Eis V, Kretzler M, Segerer S, Strutz F, Horuk R, Gröne HJ, Schlöndorff D, Anders HJ, 2004. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 66: 2264–2278.
Sousa-Pereira SR, Teixeira AL, Silva LC, Souza AL, Antunes CM, Teixeira MM, Lambertucci JR, 2006. Serum and cerebral spinal fluid levels of chemokines and Th2 cytokines in Schistosoma mansoni myeloradiculopathy. Parasite Immunol 28: 473–478.
Cherney DZ, Scholey JW, Sochett E, Bradley TJ, Reich HN, 2011. The acute effect of clamped hyperglycemia on the urinary excretion of inflammatory cytokines/chemokines in uncomplicated type 1 diabetes. Diabetes Care 34: 177–180.
Wolkow PP, Niewczas MA, Perkins B, Ficociello LH, Lipinski B, Warram JH, Krolewski AS, 2008. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol 19: 789–797.
Takebayashi K, Matsumoto S, Aso Y, Inukai T, 2006. Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients. J Diabetes Complications 20: 98–104.
Amann B, Tinzmann R, Angelkort B, 2003. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 26: 2421–2425.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 273 | 179 | 16 |
Full Text Views | 332 | 10 | 0 |
PDF Downloads | 56 | 12 | 0 |
We investigated the serum and urine chemokine levels of patients with schistosomal mansoni glomerulonephritis. This cross-sectional study was conducted in the Southeast of Brazil. Overall, 160 subjects were enrolled and divided into five groups: 1) hepatosplenic schistosomiasis with renal disease (N = 12); 2) hepatosplenic schistosomiasis without renal disease (N = 68); 3) hepatointestinal schistosomiasis (N = 27); 4) glomerulopathy caused by other diseases (N = 22); and 5) healthy controls (N = 31). The patients with microalbuminuria > 30 mg in 24 hours were considered to have renal disease. The sera and urine chemokines CCL2, CCL3, CCL5, CCL11, and CXCL8 were measured using an enzyme-linked immunosorbent assay test. A similar profile was observed between the patients with schistosomal glomerulopathy and the patients with glomerulopathy caused by other diseases, with the exception of serum CCL2 ≤ 634.3 pg/mL. In cases with sera CCL2 > 634.3 pg/mL, the diagnosis of schistosomal glomerulopathy should be considered.
Financial support: This work has been partially supported by the FAPEMIG and CNPq/Brazil.
Authors' addresses: Alba Otoni, Izabela Voieta, and Vinícius Lins Costa Melo, Universidade Federal de Minas Gerais - Medicina Tropical, Belo Horizonte, Minas Gerais, Brazil, E-mails: albaotoni01@yahoo.com.br, voieta@uol.com.br, and vilinscm@gmail.com. Antônio Lúcio Teixeira, Federal University de Minas Gerais - Internal Medicine and Laboratory of Immunopharmacology, Belo Horizonte, Minas Gerais, E-mails: altexr@gmail.com or altexjr@hotmail.com. Carlos Maurício Antunes, Santa Casa de Misericórdia de Belo Horizonte - Epidemiologia, Belo Horizonte, Minas Gerais, Brazil, E-mail: antunesc@santacasabh.org.br. Sandra Costa Drummond, Secreatria Estadual de Saùde - Helmintologia, Belo Horizonte, Minas Gerais, Brazil, E-mail: sandracdrummond@yahoo.com.br. Valério Ladeira Rodrigues, Universidade Federal de Minas Gerais - Nephrology, Belo Horizonte, Minas Gerais, Brazil, E-mail: varodrigues@uai.com.br. José Roberto Lambertucci, Department of Infectology and Tropical Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, E-mail: lamber@uai.com.br.
Brasil, Ministério da Saúde.Secretaria de Vigilância em Saúde, 2010. Situação epidemiológica de Esquistossomose no Brasil. Grupo Técnico das Parasitárias, Sub HA/CGDT/DEVEP/SVS/MS Brasília. Available at: http://portal.saude.gov.br/portal/arquivos/pdf/situacao_esquistossomose_brasil_abril2011.pdf. Acessado em junho de 2013.
Hoffman DB, Lehman JS, Scott VC, Warren KS, Webbe G, 1979.Control of schistosomiasis: report of a workshop. Am J Trop Med Hyg 28: 249–259.
Lambertucci JR, 1993. Schistosoma mansoni: pathological and clinical aspects. Jordan P, Webbe G, Sturrock RF, eds. Human Schistosomiasis. Wallingford: Cab International, 195–225.
Lambertucci JR, dos Santos Silva LC, Andrade LM, de Queiroz LC, Carvalho VT, Voieta I, Antunes CM, 2008. Imaging techniques in the evaluation of morbidity in schistosomiasis mansoni. Acta Trop 108: 209–217.
Rodrigues VL, Otoni A, Voieta I, Antunes CM, Lambertucci JR, 2010. Glomerulonephritis in schistosomiasis mansoni: a time to reappraise. Rev Soc Bras Med Trop Nov-Dec 43: 638–642.
Lambertucci JR, Otoni A, dos Reis MA, 2007. Nephrotic syndrome in hepatosplenic schistosomiasis mansoni. Rev Soc Bras Med Trop 40: 492–493.
Lambertucci JR, Serufo JC, Gerspacher-Lara R, Rayes AA, Teixeira R, Nobre V, Antunes CM, 2000. Schistosoma mansoni: assessment of morbidity before and after control. Acta Trop 77: 101–109.
Hawkins R, 2011. New biomarkers of acute kidney injury and the cardio-renal syndrome. Korean J Lab Med 31: 72–80.
Araya CE, Wasserfall CH, Brusko TM, Mu W, Segal MS, Johnson RJ, Garin EH, 2006. A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol 21: 603–610.
Garin EH, 2000. Circulating mediators of proteinuria in idiopathic minimal lesion nephrotic syndrome. Pediatric Nephrol 14: 872–878.
Souto MF, Teixeira AL, Russo RC, Penido MG, Silveira KD, Teixeira MM, Simões E, Silva AC, 2008. Immune mediators in idiopathic nephrotic syndrome: evidence for a relation between interleukin 8 and proteinuria. Pediatr Res 64: 637–642.
Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, Warram JH, Krolewski AS, Bonventre JV, 2011. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-D-glucosaminidase. Kidney Inter 79: 464–470.
Ibrahim S, Rashed L, 2008. Correlation of urinary monocyte chemo-attractant protein-1 with other parameters of renal injury in type-II diabetes mellitus. Saudi J Kidney Dis Transpl 19: 911–917.
Mukaida N, Harada A, Matsushima K, 1998. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor. Rev Mar 9: 9–23.
Segerer S, 2003. The role of chemokines and chemokine receptors in progressive renal diseases. American J Kidney Dis 41 (Suppl 1): S15–S18.
Sun Y, Yuan S, Xu X, 2009. Expression of MCP-1 in renal tissues of patients with IgA nephropathy. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34: 1023–1028.
Silva LC, Andrade LM, de Paula IB, de Queiroz LC, Antunes CM, Lambertucci JR, 2012. Ultrasound and magnetic resonance imaging findings in Schistosomiasis mansoni: expanded gallbladder fossa and fatty hilum signs. Rev Soc Bras Med Trop Jul-Aug 45: 500–504.
Lambertucci JR, Godoy P, Neves J, Bambirra EA, Ferreira MD, 1988. Glomerulonephritis in Salmonella-Schistosoma-mansoni association. Am J Trop Med Hyg 38: 97–102.
Katz N, Chaves A, Pellegrino J, 1972. A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop São Paulo 14: 397–400.
Nyman HA, Dowling TC, Hudson JQ, Peter WL, Joy MS, Nolin TD, 2011. Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 31: 1130–1144.
Grupo de Trabalho MA, 2011. Brazilian guidelines for ambulatory monitoring of arterial pressure and III Brazilian guidelines for home monitoring of blood pressure. J Bras Nefrol Jul-Sep 33: 365–388.
Bewick V, Cheek L, Ball J, 2005. Statistics review 14: logistic regression. Crit Care 9: 112–118.
Stiglic G, Kocbek S, Pernek I, Kokol P, 2012. Comprehensive decision tree models in bioinformatics. PLoS ONE 7: e33812.
Biau G, 2012. Analysis of a random forests model. J Mach Learn Res 13: 1063–1095.
Loh WY, Shih YS, 1997. Split selection methods for classification trees. Statist Sinica 7: 815–840.
Daniel C, Schaub K, Amann K, Lawler J, Hugo C, 2007. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes 56: 2982–2989.
Sanchez-Niño MD, Sanz AB, Ihalmo P, Lassila M, Holthofer H, Mezzano S, Aros C, Groop PH, Saleem MA, Mathieson PW, Langham R, Kretzler M, Nair V, Lemley KV, Nelson RG, Mervaala E, Mattinzoli D, Rastaldi MP, Ruiz-Ortega M, Martin-Ventura JL, Egido J, Ortiz A, 2009. The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol 20: 353–362.
Hsing CH, Hsu CC, Chen WY, Chang LY, Hwang JC, Chang MS, 2007. Expression of IL-19 correlates with Th2 cytokines in uraemic patients. Nephrol Dial Transplant 22: 2230–2238.
Tesch GH, 2008. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J of Physiol Renal Physiol 294: F697–F701.
Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH, 2006. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69: 73–80.
Wu H, Wang Y, Tay YC, Zheng G, Zhang C, Alexander SI, Harris DC, 2005. DNA vaccination with naked DNA encoding MCP-1 and RANTES protects against renal injury in adriamycin nephropathy. Kidney Int 67: 2178–2186.
Vielhauer V, Berning E, Eis V, Kretzler M, Segerer S, Strutz F, Horuk R, Gröne HJ, Schlöndorff D, Anders HJ, 2004. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 66: 2264–2278.
Sousa-Pereira SR, Teixeira AL, Silva LC, Souza AL, Antunes CM, Teixeira MM, Lambertucci JR, 2006. Serum and cerebral spinal fluid levels of chemokines and Th2 cytokines in Schistosoma mansoni myeloradiculopathy. Parasite Immunol 28: 473–478.
Cherney DZ, Scholey JW, Sochett E, Bradley TJ, Reich HN, 2011. The acute effect of clamped hyperglycemia on the urinary excretion of inflammatory cytokines/chemokines in uncomplicated type 1 diabetes. Diabetes Care 34: 177–180.
Wolkow PP, Niewczas MA, Perkins B, Ficociello LH, Lipinski B, Warram JH, Krolewski AS, 2008. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J Am Soc Nephrol 19: 789–797.
Takebayashi K, Matsumoto S, Aso Y, Inukai T, 2006. Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients. J Diabetes Complications 20: 98–104.
Amann B, Tinzmann R, Angelkort B, 2003. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 26: 2421–2425.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 273 | 179 | 16 |
Full Text Views | 332 | 10 | 0 |
PDF Downloads | 56 | 12 | 0 |